Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GO42144
PACTR202203779032822Phase 1Recruiting
- Sponsor
- Genentech
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of divarasib in cancer, sponsored by Genentech. Primary endpoints: Incidence and severity of adverse events, Incidence and nature of dose-limiting toxicities and 3 more. Started Aug 2022; status: recruiting.
02
Drugs
divarasib
03
Conditions
cancer
Beyond the preview
Go deeper on PACTR202203779032822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202203779032822.